Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

Stage 1 hypertension: SBP 140-159 or DBP 90-99 Stage ... and all-cause mortality. No other drug class was significantly better than low-dose diuretics for preventing these outcomes.

Mineralys Therapeutics said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and mid-stage trials. The drug, lorundrostat, was ...

[102] SUPER enrolled WHO functional class II and III PAH patients ... studies exist in PDE5 inhibitors than in other PH medications and almost exclusively in sildenafil. Most of the ...

who have a high cardiovascular risk and whose hypertension could not be brought under control with the previous classes of medication.” A revised label in response to the release of the REMS ...

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, ...